HealthcareServices

Stomach Cancer Market Future Outlook: Strong Growth Expected Toward $7.14 Billion by 2030

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the stomach cancer market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Stomach Cancer Market?

The stomach cancer market has witnessed swift expansion in recent years. This market is projected to increase from $3.74 billion in 2025 to $4.26 billion by 2026, achieving a compound annual growth rate (CAGR) of 13.9%. Key drivers for its historical growth include a rising global incidence of gastric cancer, the prevalence of helicobacter pylori infections, increased application of chemotherapy as a standard treatment, the expansion of hospital oncology infrastructure, and enhancements in diagnostic imaging techniques.

The stomach cancer market size is poised for substantial expansion in the near future. This market is projected to reach $7.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.8%. Factors contributing to this growth during the forecast period include the increasing uptake of precision oncology, greater investment in new biologics, the broadening of immunotherapy pipelines, a heightened emphasis on detecting early-stage cancer, and enhanced accessibility to sophisticated cancer treatments. Prominent trends expected over the forecast period involve the increased application of targeted therapy regimens, a rise in the deployment of immunotherapy combinations, an amplified emphasis on early diagnostic screening, the spread of personalized treatment strategies, and the strengthened incorporation of biomarker-based testing.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp

What Drivers Are Supporting Technological Adoption In The Stomach Cancer Market?

The increasing incidence of Helicobacter pylori infection is anticipated to fuel expansion within the stomach cancer market in the future. Helicobacter pylori infection describes a condition resulting from the bacterium Helicobacter pylori, which settles in the stomach lining and can induce inflammation, ulcers, and a heightened risk of developing stomach cancer. This growing prevalence of Helicobacter pylori infection mainly stems from inadequate sanitation, which aids the fecal-oral and oral-oral spread of the bacteria, particularly in densely populated or unsanitary environments. Helicobacter pylori infection contributes to stomach cancer by inducing persistent inflammation and cellular harm to the stomach lining, culminating in precancerous alterations and tumor formation. As an illustration, in November 2024, according to the Government of Canada, a Canada-based government agency, the recurrence rate for Helicobacter pylori infection stood at 19% in 2023, with this rate fluctuating depending on factors like geographical area and age cohort. Consequently, the increasing occurrence of Helicobacter pylori infection is a key factor propelling the expansion of the stomach cancer market.

Which Segments Are Contributing To The Growth Of The Stomach Cancer Market?

The stomach cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Adenocarcinoma: Intestinal Type, Diffuse Type

2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma

3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors

4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid

5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

Which Trends Are Influencing The Development Of The Stomach Cancer Market?

Major entities within the stomach cancer treatment market are concentrating on developing advanced solutions, such as claudin (CLDN18.2)-targeted cytolytic antibody therapy, to enhance the precision of first-line treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. This claudin (CLDN18.2)-targeted cytolytic antibody therapy involves a monoclonal antibody designed to selectively bind to CLDN18.2-expressing tumor cells, inducing cytotoxic effects when combined with chemotherapy, thereby improving both progression-free and overall survival outcomes. For instance, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical company, launched Vyloy (zolbetuximab-clzb), a claudin (CLDN18.2)-directed cytolytic antibody for gastric and gastroesophageal junction (GEJ) cancer treatment. This innovative biologic therapy is administered intravenously alongside fluoropyrimidine- and platinum-containing chemotherapy, demonstrating a median progression-free survival benefit of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. This therapy specifically targets CLDN18.2-positive cancer cells, reduces off-target toxicity, and increases treatment specificity, marking a significant advancement in personalized oncology for advanced gastric cancer.

Who Are The Top-Performing Companies In The Stomach Cancer Market In Recent Years?

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc, Daiichi Sankyo Company Limited, BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Zai Lab Limited, MacroGenics Inc., Astellas Pharma Inc., Ipsen Group, AbbVie Inc., Bayer AG, Ono Pharmaceutical Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Which Region Currently Holds The Largest Share Of The Stomach Cancer Market?

North America was the largest region in the stomach cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Stomach Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25913&type=smp

Browse Through More Reports Similar to the Global Stomach Cancer Market 2026, By The Business Research Company

Tumor Ablation Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-ablation-global-market-report

Esophageal Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Gastric Cancer Diagnostic Procedure Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795